Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

In the treatment of COVID-19, antiviral drug remdesivir has emerged as a promising candidate. Remdesivir works by disrupting the virus’s ability to replicate, but its exact mechanism has remained a ...

Since the emergence of SARS-CoV-2 in 2019, the virus has accrued a variety of mutations to infect its human hosts more effectively. Certain antiviral treatments work by increasing the rate of these ...

A drug once designed for dengue virus, then quietly abandoned by industry, is suddenly back in the spotlight, and it may be ...

Coronavirus models are seen with a colorized image of a scanning electron micrograph of a cell (red) infected with the Omicron strain of the virus (blue). (NIAID) The coronavirus has been a shifty foe ...

Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works.

A drug used to treat coronavirus infections in cats has shown early promise in lab-based studies on the SARS-CoV2 virus which causes Covid-19 in people. A drug used to treat coronavirus infections in ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide ...

In a recent study posted as an accepted manuscript in the journal Clinical Infectious Diseases, researchers from the University of Oklahoma described three drugs with antiviral activity against the ...

Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for HIV, offering patients a twice-yearly injection to reduce the risk of ...

GAINESVILLE, Fla. -- A rabbit virus currently being developed for cancer therapy can be paired with one of several existing drugs to deliver a more potent punch to a deadly type of brain tumor cell, ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...